Company intelligence / Profile preview
PhilERA
Auckland, Auckland, New Zealand
- Ownership
- Private
- Development stage
- Other
01
Overview
PhilERA is a New Zealand-based biopharmaceutical company focused on developing novel copper-chelating therapies for the treatment of metabolic and rare diseases. Founded by the co-founders of Protemix Corporation, the company acquired Protemix's intellectual property assets out of liquidation to revive its therapeutic programs. PhilERA's lead research centers on triethylenetetramine (TETA) formulations, including triethylenetetramine disuccinate, a highly stable salt form of trientine with improved bioavailability. The company's pipeline targets copper-mediated oxidative stress to treat diabetic cardiomyopathy, diabetic nephropathy, and Wilson's disease.
- Therapeutic areas
- CardiovascularEndocrinologyNephrologyRare Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on PhilERA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PhilERA.